NIAID - National Institute of Allergy and Infectious Diseases
ABSTRACT/PROJECT SUMMARY Acute Graft-versus-Host Disease (aGVHD) remains a critical barrier to clinical success after allogeneic hemato- poietic cell transplantation (allo-HCT) in patients with high-risk hematologic malignancies and non-malignant diseases. The current treatment options are limited and rely heavily on non-specific immunosuppression with high-dose glucocorticoids, which is only partially effective while increasing infection risk and potentially abating the protective Graft-versus-Leukemia (GVL) effect. Emerging evidence highlights the gastrointestinal (GI) tract as a pivotal driver of systemic alloimmunity, but the exact biological pathways involved in the interface between the GI tract and the immune system are incompletely understood, which impedes the development of novel targeted anti-aGVHD approaches. This proposal seeks to investigate the mechanisms of GI-driven T cell repro- gramming during aGVHD to identify novel therapeutic targets. We hypothesize that GI-derived T cells mediate systemic aGVHD-induced immunopathology while being dispensable for the GVL effect, which we will test in the three Specific Aims. Aim 1 will examine how GI-driven reprogramming impacts donor T cell pathogenicity. We will use photoconvertible Dendra2 donor mice to trace, profile, and functionally characterize GI-reprogrammed T cells as they traffic to distal organs during multiorgan aGVHD. Aim 2 will evaluate genetic (Itgb7-mutant T cells) and pharmacologic (anti-MadCAM-1 antibodies) strategies to block T cell trafficking to the GI tract, thereby mitigating extra-GI immunopathology in skin/esophageal aGVHD model induced by transplantation of OVA-spe- cific OT-I T cells to B6-K14.OVA recipient mice with keratinocyte-restricted OVA expression. Aim 3 will employ allo-HCT models in which aGVHD and GVL are mediated by distinct T cell subsets to determine whether GI- driven reprogramming affects the cytotoxic function of tumor-specific T cells in vivo. This project will provide foundational insights into tissue-specific immune regulation and inform the development of precision therapies to control aGVHD while preserving GVL. These findings promise broader relevance to T cell-mediated alloim- mune and autoimmune diseases, paving the way for clinical translation.
Up to $436K
2028-01-31
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
One-time $749 fee · Includes AI drafting + templates + PDF export
Dynamic Cognitive Phenotypes for Prediction of Mental Health Outcomes in Serious Mental Illness
NIMH - National Institute of Mental Health — up to $18.3M
Leveraging Artificial Intelligence to Predict Mental Health Risk among Youth Presenting to Rural Primary Care Clinics
NIMH - National Institute of Mental Health — up to $15.0M
Feasibility of Genomic Newborn Screening Through Public Health Laboratories
OD - NIH Office of the Director — up to $14.4M
WOMEN'S HEALTH INITIATIVE (WHI) CLINICAL COORDINATING CENTER - TASK AREA A AND A2
NHLBI - National Heart Lung and Blood Institute — up to $10.2M
Metal Exposures, Omics, and AD/ADRD risk in Diverse US Adults
NIA - National Institute on Aging — up to $10.2M
NHLBI CATALYZE PRECLINICAL SERVICES: PROJECTS YR. 4 - TASK ORDER 5
NHLBI - National Heart Lung and Blood Institute — up to $10.0M